1. Challenges in RAS Wild-Type mCRC

3. Introduction

4. Decision-Making Algorithm for First-Line Treatment of mCRC

5. Clinical Utility of ctDNA

6. Treatment of mCRC: ESMO Guidelines

7. First-Line Treatment for Right-Sided Tumors

8. First-Line Treatment: Patient Preferences

9. Optimal Treatment Choices for Disease Control by Location of Primary Tumor*

10. CRYSTAL and FIRE-3 Trials

11. Second-Line Therapy for mCRC

12. Mechanisms of Resistance to Anti-EGFR Pathways

13. Cetuximab Beyond Progression: CAPRI GOIM Study PFS According to KRAS, NRAS, BRAF, and PIK3CA Status

14. Continuation/Maintenance With Anti-EGFR Treatment Involves Managing Toxicity Profiles

15. Retest for RAS?

16. Tailoring the Treatment Strategy to Patient and Tumor Characteristics

17. ASPECCT Trial: OS and PFS Results Patients With Prior Bevacizumab Treatment in Chemorefractory wtKRAS exon 2 mCRC

18. Bevacizumab Followed by Anti-EGFR Therapy: Unanswered Questions

19. Cetuximab Rechallenge: Rationale (Santini Hypothesis)

20. Time From Last Treatment With EGFR mAbs Correlates With Quantification of KRAS Mutations Detected in ctDNA

21. Strategies to Address Mechanisms of Resistance

22. CRICKET Study: Good Response to Cetuximab Rechallenge in Irinotecan‑Refractory mCRC

23. Rechallenge With Anti-EGFR Therapy: FIRE-4 Study

24. Key Points of Studies Using Rechallenge With Anti-EGFR

25. Determining Wash-Out Periods

26. Monitoring for Resistance Using Liquid Biopsy May Allow Timely Decision Making

27. Conclusions

28. Abbreviations

29. Abbreviations (cont)